ViiV’s Rukobia cleared in EU as rescue HIV therapyThe European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment Share XViiV’s Rukobia cleared in EU as rescue HIV therapyhttps://pharmaphorum.com/news/viivs-rukobia-cleared-in-eu-as-rescue-hiv-therapy/
ViiV launches digital triage service for HIV patients with London hospitalViiV Healthcare and London’s Westminster Hospital NHS Foundation Trust have launched a digital triage service for HIV patients Share XViiV launches digital triage service for HIV patients with London hospitalhttps://pharmaphorum.com/news/viiv-launches-digital-triage-service-for-hiv-patients-with-london-hospital/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
ViiV’s two-drug HIV therapy Dovato gets Japanese approvalOne of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new Share XViiV’s two-drug HIV therapy Dovato gets Japanese approvalhttps://pharmaphorum.com/news/viivs-two-drug-hiv-therapy-dovato-gets-japanese-approval/
ViiV files first-in-class HIV drug in EuropeViiV Healthcare has filed its new HIV drug fostemsavir for approval in Europe, a few weeks after the Share XViiV files first-in-class HIV drug in Europehttps://pharmaphorum.com/news/viiv-files-first-in-class-hiv-drug-in-europe/
FDA knocks back ViiV, J&J’s long-acting HIV regimenPeople with HIV hoping to be freed from daily doses of tablets will have to wait a little Share XFDA knocks back ViiV, J&J’s long-acting HIV regimenhttps://pharmaphorum.com/news/fda-knocks-back-viiv-jjs-long-acting-hiv-regimen/
ViiV presses go on FDA filing for first-in-class HIV drug fostemsavirViiV Healthcare has fulfilled its pledge of submitting its new HIV drug fostemsavir for approval before year end, Share XViiV presses go on FDA filing for first-in-class HIV drug fostemsavirhttps://pharmaphorum.com/news/viiv-presses-go-on-fda-filing-for-first-in-class-hiv-drug-fostemsavir/
ViiV files monthly HIV jab in EuropeViiV Healthcare has submitted its once-monthly two-drug injectable therapy for HIV to the EMA, setting up possible approval Share XViiV files monthly HIV jab in Europehttps://pharmaphorum.com/news/viiv-files-monthly-hiv-jab-in-europe/
ViiV’s first-in-class HIV drug on course for filings this yearViiV Healthcare has new data on its first-in-class HIV drug fostemsavir that back up its long-term effects, and Share XViiV’s first-in-class HIV drug on course for filings this yearhttps://pharmaphorum.com/news/viivs-first-in-class-hiv-drug-on-course-for-filings-this-year/